PLL Therapeutics

PLL Therapeutics enrolls first patient in phase I/II trial of drug candidate PLL001 for Amyotrophic Lateral Sclerosis (ALS)

Multi-stage Australian study will evaluate safety of PLL001 in 12 ALS patients, testing three different doses along with placebo 140 ALS patients will participate in second stage of study to test efficacy of PLL001 Trial will also evaluate world’s very first early-stage diagnostics paired with poly-targeted therapeutic approach, bringing promise of new standard to combat...
10 Avenue Roger Lapébie 33140 Villenave d’Ornon France

+33(0)5 54 07 06 61